scholarly journals Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study

2012 ◽  
Vol 106 (12) ◽  
pp. 2016-2024 ◽  
Author(s):  
A Jakubowska ◽  
◽  
D Rozkrut ◽  
A Antoniou ◽  
U Hamann ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Risk ◽  
Multicenter Study ◽  
Ovarian Cancer Risk ◽  
Breast And Ovarian Cancer ◽  
Mutation Carriers

scholarly journals Breast and Ovarian Cancer Risk and Risk Reduction in Jewish BRCA1/2 Mutation Carriers

2012 ◽  
Vol 30 (12) ◽  
pp. 1321-1328 ◽  
Author(s):  
Brian S. Finkelman ◽  
Wendy S. Rubinstein ◽  
Sue Friedman ◽  
Tara M. Friebel ◽  
Shera Dubitsky ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Cancer Risk ◽  
Risk Reduction ◽  
Ovarian Cancer Risk ◽  
Jewish Women ◽  
Cancer Risks ◽  
Breast And Ovarian Cancer ◽  
Mutation Carriers ◽  
Significant Difference

Purpose Mutations in BRCA1/2 dramatically increase the risk of both breast and ovarian cancers. Three mutations in these genes (185delAG, 5382insC, and 6174delT) occur at high frequency in Ashkenazi Jews. We evaluated how these common Jewish mutations (CJMs) affect cancer risks and risk reduction. Methods Our cohort comprised 4,649 women with disease-associated BRCA1/2 mutations from 22 centers in the Prevention and Observation of Surgical End Points Consortium. Of these women, 969 were self-identified Jewish women. Cox proportional hazards models were used to estimate breast and ovarian cancer risks, as well as risk reduction from risk-reducing salpingo-oophorectomy (RRSO), by CJM and self-identified Jewish status. Results Ninety-one percent of Jewish BRCA1/2-positive women carried a CJM. Jewish women were significantly more likely to undergo RRSO than non-Jewish women (54% v 41%, respectively; odds ratio, 1.87; 95% CI, 1.44 to 2.42). Relative risks of cancer varied by CJM, with the relative risk of breast cancer being significantly lower in 6174delT mutation carriers than in non-CJM BRCA2 carriers (hazard ratio, 0.35; 95% CI, 0.18 to 0.69). No significant difference was seen in cancer risk reduction after RRSO among subgroups. Conclusion Consistent with previous results, risks for breast and ovarian cancer varied by CJM in BRCA1/2 carriers. In particular, 6174delT carriers had a lower risk of breast cancer. This finding requires additional confirmation in larger prospective and population-based cohort studies before being integrated into clinical care.

Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland

2005 ◽  
Vol 95 (2) ◽  
pp. 105-109 ◽  
Author(s):  
Jacek Gronwald ◽  
Tomasz Byrski ◽  
Tomasz Huzarski ◽  
Cezary Cybulski ◽  
Ping Sun ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Risk ◽  
Brca1 Mutation ◽  
Lifestyle Factors ◽  
Ovarian Cancer Risk ◽  
Breast And Ovarian Cancer ◽  
Mutation Carriers

scholarly journals Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

2010 ◽  
Vol 19 (11) ◽  
pp. 2859-2868 ◽  
Author(s):  
Christoph Engel ◽  
Beatrix Versmold ◽  
Barbara Wappenschmidt ◽  
Jacques Simard ◽  
Douglas F. Easton ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Risk ◽  
Brca2 Mutation ◽  
Ovarian Cancer Risk ◽  
Breast And Ovarian Cancer ◽  
Brca1 And Brca2 ◽  
Mutation Carriers

Younger birth cohort correlates with higher breast and ovarian cancer risk in EuropeanBRCA1 mutation carriers

2005 ◽  
Vol 26 (6) ◽  
pp. 583-589 ◽  
Author(s):  
Regina Kroiss ◽  
Verena Winkler ◽  
Diana Bikas ◽  
Elisabeth Fleischmann ◽  
Claudia Mainau ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Risk ◽  
Birth Cohort ◽  
Ovarian Cancer Risk ◽  
Breast And Ovarian Cancer ◽  
Mutation Carriers

scholarly journals Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

2014 ◽  
Vol 24 (1) ◽  
pp. 308-316 ◽  
Author(s):  
Paolo Peterlongo ◽  
Jenny Chang-Claude ◽  
Kirsten B. Moysich ◽  
Anja Rudolph ◽  
Rita K. Schmutzler ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Risk ◽  
Brca2 Mutation ◽  
Ovarian Cancer Risk ◽  
Genetic Modifiers ◽  
Breast And Ovarian Cancer ◽  
Brca1 And Brca2 ◽  
Mutation Carriers

Determinants of serum adiponectin levels: a cross-sectional study

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Azar Sattarinezhad ◽  
Akbar Rasekhi Kazerouni ◽  
Gholamhossein Ranjbar Omrani ◽  
Mesbah Shams
Keyword(s):  
Ovarian Cancer ◽  
Germ Line ◽  
Brca Mutation ◽  
Bilateral Mastectomy ◽  
Ovarian Cancer Risk ◽  
Breast And Ovarian Cancer ◽  
Double Blind ◽  
Cross Sectional ◽  
Mutation Carriers

Abstract Objectives To review non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes. Content Women with a gBRCA1 or 2 mutations face a high cumulative breast and ovarian cancer risk. While bilateral mastectomy (PBM) and bilateral salpingo-oophrectomy (PBSO) profoundly reduce the respective cancer risks, they are also associated with considerable side effects. There is therefore an urgent need for alternative and non-surgical risk reduction options. Tamoxifen and aromatase inhibitors have both been evaluated in secondary prevention, but their benefit in primary prevention is currently unknown in BRCA mutation carriers. In addition, their use is compromised by their side effect profile which makes them less appealing for a use in chemoprevention. Summary and outlook Denosumab is a well-tolerated osteoprotective drug, which has been demonstrated to have a potential preventive effect particularly in BRCA1-deficient models in vitro. The prospectively randomized double-blind BRCA-P trial is currently investigating the preventative effect of denosumab in healthy BRCA1 germ line mutation carriers.

Sign in / Sign up

Export Citation Format

Share Document